Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Salvage Chemotherapy in r/r cHL
NCT04838652Phase 2Recruiting
- Sponsor
- University of Cologne
- Start
- Mar 2024
- Primary completion
- May 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in classical Hodgkin lymphoma (cHL), sponsored by University of Cologne. Started Mar 2024; status: recruiting.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT04838652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04838652.